6,119 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Bought by Fox Run Management L.L.C.

Fox Run Management L.L.C. acquired a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 6,119 shares of the company’s stock, valued at approximately $518,000.

Other large investors have also modified their holdings of the company. Assetmark Inc. acquired a new stake in shares of Axsome Therapeutics during the 4th quarter valued at about $52,000. R Squared Ltd purchased a new position in Axsome Therapeutics during the fourth quarter worth approximately $64,000. KBC Group NV grew its holdings in Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after purchasing an additional 385 shares during the period. Xponance Inc. increased its position in shares of Axsome Therapeutics by 11.6% in the fourth quarter. Xponance Inc. now owns 2,659 shares of the company’s stock valued at $225,000 after buying an additional 277 shares in the last quarter. Finally, Corient Private Wealth LLC acquired a new position in shares of Axsome Therapeutics during the 4th quarter worth approximately $239,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Performance

NASDAQ AXSM opened at $120.36 on Wednesday. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The stock’s fifty day moving average is $118.07 and its two-hundred day moving average is $100.65. The firm has a market capitalization of $5.87 billion, a P/E ratio of -20.09 and a beta of 1.00. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The firm had revenue of $118.77 million for the quarter, compared to analysts’ expectations of $117.83 million. On average, research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on AXSM shares. Robert W. Baird lifted their price target on shares of Axsome Therapeutics from $132.00 to $160.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and issued a $200.00 target price on shares of Axsome Therapeutics in a research report on Thursday, March 6th. Royal Bank of Canada boosted their target price on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $153.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Finally, Truist Financial boosted their price objective on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $167.36.

Insider Buying and Selling at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 22.40% of the stock is currently owned by company insiders.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.